National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lesinurad (Zurampic®) for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.

NCPE Assessment Process Ongoing
Rapid review received 15/03/2017
Rapid review completed 20/03/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 29/03/2017
Pre-submission consultation with Applicant 22/05/2017
Anticipated date of submission Q4 2017
Current status Awaiting applicant submission 

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven